Loading ChartRhythms
Preparing market rhythm analysis...
Preparing market rhythm analysis...
Full Rhythm Report
STE • Stock • Health Care / Health Care Equipment
Cross-Horizon Read
STE's evidence points supportive across the available windows.
Generated 2026-10-05T11:20:00.000Z • Evidence b673bc56
Price Data
Quote and historical price data are unavailable right now.
ChartRhythms displays a price chart only when real historical time-series data is available. No estimated or synthetic chart is shown.
0–3 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
• Additional dated, company-specific coverage in the 0–3 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
4–21 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
22–90 days
The 22–90 days evidence set currently reads bullish.
Supporting articles
4
Opposing articles
0
Neutral articles
11
Confidence basis
Supporting evidence
• STERIS (NYSE:STE): A Quality Investment Built for Long-Term Compounding
• STERIS Q1 Earnings Call Highlights
• STERIS chooses Sanford for $600 million manufacturing campus
• Should STERIS' (STE) Record Chemistries Investment and Dividend Hike Require Action From Investors?
Help improve this analysis
This feedback is saved locally for the MVP. Later, ChartRhythms can use this feedback to improve the strategy engine.
Important:
ChartRhythms provides source-based market summaries for research and informational purposes only. This is not financial advice and not a recommendation to buy, sell, or hold any security.
• Additional dated, company-specific coverage in the 4–21 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
Opposing evidence
No opposing articles were found in this window.
Catalysts
• STERIS Stock Outlook: Is Wall Street Bullish or Bearish?
• STERIS Q1 Earnings Call Highlights
• Piper Sandler Reiterates Overweight on Steris, Raises Price Target to $275
• UBS Maintains Buy on Steris, Lowers Price Target to $270
• STERIS plc (STE) Q1 2027 Earnings Call Transcript
Risks
• Should Investors Buy STERIS as Growth Meets Reasonable Valuation?
Next proof points
• Continued coverage in the 22–90 days window confirming the current read.
Strengthens if
• Supporting evidence (4) grows relative to opposing evidence (0) in this window.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (4) in this window.
Showing 8 of 15 sources
STERIS Stock Outlook: Is Wall Street Bullish or Bearish?
Yahoo • 2026-08-26 • Neutral
Open via Finnhub →Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?
Yahoo • 2026-08-21 • Mixed
Open via Finnhub →Should Investors Buy STERIS as Growth Meets Reasonable Valuation?
Yahoo • 2026-08-20 • Mixed
Open via Finnhub →STERIS (NYSE:STE): A Quality Investment Built for Long-Term Compounding
ChartMill • 2026-08-18 • Bullish
Open via Finnhub →Q2 Rundown: STERIS (NYSE:STE) Vs Other Surgical Equipment & Consumables - Diversified Stocks
Yahoo • 2026-08-17 • Neutral
Open via Finnhub →Piper Sandler Reiterates Overweight on Steris, Raises Price Target to $275
Benzinga • 2026-08-07 • Neutral
Open via Finnhub →